The global Implantable Cardioverter Defibrillator (ICD) market garnered revenue around USD 6.5 Billion in 2019 and projected to reach USD 10.5 Billion in 2027, with at a compound annual growth rate of 6% throughout the estimate period from 2020 to 2027.
Implantable Cardioverter Defibrillator (ICD) is used to record the heart's activity and treat dangerous ventricular arrhythmias with an electrical shock or pulse to the heart. If an arrhythmia is detected, the ICD delivers a high voltage shock to correct the irregularity in that chamber. A dual-chamber ICD monitors the electrical activity in two chambers of the heart (an atrium and a ventricle) and delivers electric pulses to one or both chambers in the event of an arrhythmia.
According to a study published in the Endocrinology, Diabetes & Metabolism Case Reports in 2018, more than 26% of the patients diagnosed with type 2 diabetes were estimated to suffer from Silent Myocardial Ischemia (SMI). Moreover, it is reported that the prevalence of diabetes has increased. This is illustrative by the fact sheet of the World Health Organization published in 2018. According to the report, the global prevalence of diabetes among individuals aged 18 years or more was about 8.5% in 2018. Thus, it is interpreted that the rising prevalence of diabetes provides a necessary driving force for the myocardial ischemia segment and ICD market to expand during the forecast period.
Higher success rates of implantable cardioverter defibrillators for the treatment of patients suffering from myocardial ischemia and acute myocardial infarction would fuel this market.
Technological advancements in subcutaneous ICD technology help in minimally invasive procedures and have high success rate for the treatment of myocardial ischemia and acute myocardial infarction. This is likely to boost the market during the forecast period.
This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.
The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Implantable Cardioverter Defibrillator (ICD) market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Implantable Cardioverter Defibrillator (ICD) market growth.
The global Implantable Cardioverter Defibrillator (ICD) market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.
Major manufacturers analysed under this study comprises:
Abbott Laboratories (US)
BIOTRONIK (Germany)
Boston Scientific Corporation (US)
Medtronic (Ireland)
MicroPort Scientific Corporation (China)
Koninklijke Philips N.V. (Netherlands)
Nihon Kohden Corporation (Japan)
Progetti Srl (Italy)
Fukuda Denshi Co., Ltd (Japan)
Getinge (Sweden)
ZOLL Medical Corporation (US)
This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:
By Product
Regular ICD:
Cardiac resynchronization therapy defibrillators (CRT-D):
Subcutaneous-ICD (S-ICD):
Others:
By Indication
Myocardial ischemia:
Acute myocardial infarction:
Electrolyte imbalance and drug toxicity:
By End User
Hospitals and clinics:
Ambulatory surgical centers:
Regional Analysis and Forecast
Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:
North America
? U.S.
? Canada
Europe
? Germany
? U.K.
? Italy
? France
? Rest of EU
Asia Pacific
? China
? India
? Japan
? Southeast Asia
? Rest of APAC
Central & South America
? Brazil
? Argentina
? Rest of Central & South America
Middle East and Africa
? UAE
? Saudi Arabia
? Rest of MEA
Request Customization
Get a Sample
Get a Sample
Request Customization